154 results about "Lymph Cell" patented technology

The present invention provides improved and / or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. The methods may comprise gene-editing at least a portion of the TILs to enhance their therapeutic efficacy. Such TILs find use in therapeutic treatment regimens.

The present invention provides improved and / or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.

The invention discloses a gene-edited tumor infiltrating lymphocyte and a T cell receptor engineered T cell and application thereof in immunotherapy. According to the invention, NR4A1 and / or NR4A2 and / or NR4A3 genes are / is knocked out from tumor infiltrating lymphocytes or T cell receptor engineered T cells, so that the multiplication capacity and the anti-tumor capacity of the tumor infiltrating lymphocytes or T cell receptor engineered T cells are improved.

The invention provides pathological tissue section dyeing equipment and method. The method comprises the following steps: dividing a to-be-dyed lymphatic tissue section into a plurality of dyeing partitions according to the structural characteristics of lymphocyte tissues in the to-be-dyed lymphatic tissue section; dyeing agents with different concentrations are applied to different dyeing partitions according to the reference light transmittance of the lymphocyte tissue to obtain color gradient vectors of the lymphocyte tissue slices, light absorption characteristics of the dyeing partitions are measured through a photometer, and dyeing characteristics are determined based on the light absorption characteristics and the color gradient vectors; obtaining a dyeing image after dyeing the lymph tissue section, extracting deep features of the dyeing partitions from the dyeing image, and determining a dyeing loss value when dyeing the dyeing partitions based on the deep features and the dyeing features; and based on the dyeing loss value, carrying out self-adaptive adjustment on the dyeing agent concentration of each dyeing zone. By adopting the scheme provided by the invention, optimal adjustment on the concentration of the coloring agent in the sample dyeing process can be realized based on the characteristic difference of the cell tissues at different parts.

The present invention relates to a system and a method for measuring and analyzing minimal residual disease (MRD) in pediatric B-cell precursor acute lymphoblastic leukemia (B-ALL) using multiparameter flow cytometry (MPFC). The invention finds application in clinical diagnostics and hematology-oncology for quantifying MRD in B-ALL patients with high sensitivity and specificity, needed for risk stratification, monitoring treatment response, and informing therapeutic decisions. The system comprises interconnected subsystems including an acquisition subsystem with an MPFC instrument, a control and file generation subsystem, and an analytical subsystem. The analytical subsystem incorporates modules for sequential data reduction, automated data cleaning, automated unsupervised data clustering, and interactive cluster analysis. Key advantages include high MRD detection sensitivity (e.g., 10⁻⁵ or 0.001%) and high specificity, without reliance on reference samples or supervised machine learning models, making it applicable in laboratories with different measuring equipment and using different panels of antibodies for identification of leukemic cells.

The invention discloses an application of a pyrrosia lingua aqueous extract in preparation of a medicine for preventing and treating radioactive intestinal injury. Radioactive intestinal injury is a common complication of ionizing radiation, and has main pathological characteristics of intestinal mucosal barrier destruction, excessive release of inflammatory factors, increase of oxidative stress level and hematopoiesis and immune function inhibition. At present, no effective and safe prevention and treatment medicine is available. It is found for the first time that the pyrrosia lingua aqueous extract can inhibit expression (IL-6, TNF-alpha and IL-1beta) of inflammatory factors of radiation-induced MODE-K cells and relieve the oxidative stress level (malondialdehyde (MDA) is reduced, and the content of superoxide dismutase (SOD) and glutathione (GSH) is increased). In animal experiments, the pyrrosia lingua aqueous extract can reduce the levels of TNF-alpha and IL-1beta inflammatory factors in serum of irradiated mice and improve oxidative stress disorders such as MDA increase, SOD and GSH decrease and the like; the reduction of leukocytes and lymphocytes is relieved; the length of intestinal villus is promoted and recovered; the proportion of Ki67 positive cells in a crypt region is increased, so that the regeneration capacity of intestinal epithelial cells is enhanced. The pyrrosia lingua aqueous extract disclosed by the invention provides an experimental basis and an application prospect for developing a novel medicine for preventing and treating the radioactive intestinal injury.

The application discloses a use of Ejiao Qianggu oral liquid in regulating immunity, and particularly relates to an improving effect of the Ejiao Qianggu oral liquid on an immune system, which is realized by the following aspects. On one hand, the Ejiao Qianggu oral liquid promotes proliferation and transformation (mainly early T lymphocytes and part of B lymphocytes) and active functions of spleen lymphocytes; on the other hand, the Ejiao Qianggu oral liquid improves phagocytosis of macrophages. The Ejiao Qianggu oral liquid has the following characteristics: firstly, the Ejiao Qianggu oral liquid acts on early lymphocyte maturation, and has no significant effect on proliferation of peripheral blood lymphocytes; secondly, the Ejiao Qianggu oral liquid can significantly act on immune target organs, thymus and spleen tissues, and does not excessively stimulate the spleen, unlike positive drugs such as colony stimulating factor which can cause significant edema of the spleen; and thirdly, the Ejiao Qianggu oral liquid has a significant recovery effect on body weight, white blood cells, lymphocytes, red blood cells and hemoglobin in blood of patients with low immunity.

The invention discloses preparation of a methoxyl derivative and application of the methoxyl derivative in pharmacy. The methoxy derivative as shown in the formula I has good anti-tumor activity, and the anti-tumor effect is effectively achieved through the growth inhibition and killing effect on tumor cells. The methoxyl derivative not only can inhibit the growth of CT26 transplanted tumors, but also can promote the activation and infiltration of lymphocytes in an in-vivo tumor microenvironment. Meanwhile, the compound also has a remarkable inhibiting effect on the growth of mouse colon cancer CT26 cell strains in vitro.

The disclosure provides a chimeric antigen receptor (CAR) polypeptide having an antigen binding domain comprising an extracellular lectin which specifically binds to glycoproteins expressed on the surface of target cells. Also provided herein are engineered lymphocytes expressing the CAR polypeptide, a nucleic acid molecule encoding the CAR polypeptide, and methods of treating cancer.

The utility model belongs to the technical field of medical instruments, and particularly relates to a rapid lymphocyte separating tube with adjustable volume, which comprises a tube body, a separating device, a threaded section and a rotary moving rod, the threaded section is arranged on the inner wall of the middle of the tube body, the separating device is connected inside the tube body in a sliding manner through the threaded section, and the rotary moving rod is arranged on the inner wall of the middle of the tube body. The separating device is provided with a central separating hole for a sample to pass through during centrifugation, and the rotary moving rod is clamped with the separating device through the central separating hole. According to the device, the positions of the partition plates can be adjusted according to blood of different volumes, so that the requirement of rapidly separating lymphocytes from the blood of different volumes is met, and time and resources are saved.

The present disclosure relates to an apparatus including one or more processors configured to receive a digitized image of a region of tissue demonstrating a disease, and containing cellular structures represented in the digitized image, each of the cellular structures being associated with a cell category of a plurality of cell categories; select a cellular structure of the cellular structures based on the cell category for the cellular structure; for the cellular structure selected, compute a set of contextual features; assign, based on the set of contextual features, the cellular structure to at least one cluster of a plurality of clusters; compute cluster features, the cluster features describing characteristics of the at least one cluster of the plurality of clusters; and generate a prediction that describes a pathologic or phenotypic state of the disease based, at least in part, on the cluster features and / or the set of contextual features.

The utility model provides a device convenient for storing donor lymphocytes, and relates to the field of medical instruments. The device comprises a positioning support frame which is sequentially provided with a plurality of storage spaces at intervals in the direction from the top to the bottom; the storage boxes are used for placing and storing donor lymphocyte test tubes, the number of the storage boxes is equal to that of the storage spaces, and the storage boxes are respectively matched with the storage spaces one by one; any storage box is matched with the matched storage space in an inserted mode, and the insertion ports of the multiple storage spaces are located on the same side of the positioning supporting frame. The limiting rod is detachably matched with the positioning support frame, simultaneously penetrates through the insertion ports of the plurality of storage spaces and is used for limiting the plurality of storage boxes in the plurality of storage spaces respectively; and the lifting rod is arranged at the top of the positioning support frame. According to the device, the test tube storage stability is improved, shaking and toppling during transferring are avoided, and the sample damage and pollution risk is reduced.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a cancer suppressor gene SLC26A11 in hyperleukocyte acute B lymphocytic leukemia. The invention discloses an application of a cancer suppressor gene SLC26A11 as a specific molecular marker in preparation of induction treatment reaction, prognosis and risk assessment of high leukocyte acute B lymphocytic leukemia of children, and an application in improvement of sensitivity of chemotherapeutic drugs for high leukocyte acute B lymphocytic leukemia of children. The SLC26A11 is used as a potential target, so that a personalized treatment scheme is provided for HALL patients, the toxic and side effects of chemotherapeutic drugs are reduced, and the treatment effect is improved.

A method for reprogramming native CD4+ T-cells is provided. The method comprises incubating the CD4+ T-cells with a Class 1 HDAC inhibitor for a period of time sufficient to increase cytotoxicity of the CD4+ T-cells in comparison to the cytotoxicity of native CD4+ T-cells. The method may be utilized to prepare cytotoxic tumor infiltrating CD4+ T-cells for use to treat cancer, including MHC-I deficient cancers.

The invention discloses a fracture risk prediction method and system, and relates to the technical field of health management. According to the prediction method, serious sarcopenia is selected to diagnose and assess the sarcopenia state, the ratio of monocytes to lymphocytes reflects the immune inflammation level, the prediction model is constructed in combination with the femoral neck bone mineral density T value, and the fracture risk influence factors are comprehensively covered; and the risk identification capability on special high-risk groups with sarcopenia, immune dysfunction and the like is effectively improved. And secondly, only three target independent variables are selected, and the three target independent variables are indexes which can be directly obtained or simply calculated in clinical routine examination, so that the data collection difficulty is greatly reduced. Meanwhile, the prediction model is visualized through a column diagram, complex calculation is not needed, a clinician can quickly inquire the fracture risk score through the actual value of the target subject, and the method is suitable for being efficiently applied to conventional outpatient service, hospitalization and other scenes.

This invention belongs to the field of biomedical technology, specifically relating to a culture reagent composition and method for organoids from hematologic malignancies. The invention first provides a reagent composition for culturing organoids from hematologic malignancies, including acute lymphoblastic leukemia or acute myeloid leukemia; the reagent composition includes a bone marrow microenvironment mimicking matrix reagent and a specific culture medium. Using the reagent composition of this invention, hematologic malignancies can be cultured efficiently with high survival rates. Furthermore, the bone marrow microenvironment mimicking matrix component used in this invention, compared to the commonly used Matrigel matrix in the field, allows for more accurate phenotypic differentiation of hematologic malignancies.

The invention provides systems and methods for determining and predicting the effect of providing a population of tumor infiltrating lymphocytes (TILs) on a condition associated with an entity, for example the effect of providing a population of tumor infiltrating lymphocytes (TILs) on a subject having cancer. The systems and methods rely on acquiring a computer readable analytical signature from a sample of the entity, obtaining a trained model output value for the entity by inputting the computer readable analytical signature into a tier trained model panel, and classifying the entity based upon the trained model output value with a time-to-event class in an enumerated set of time-to-event classes, each of whom is associated with a different effect of providing a population of TILs to the entity.The invention provides methods of treating cancer in a patient by administering a therapeutically effective population of TILs to the patient, which is at the same determined to be likely to benefit from the administration of TILs comparative to other cancer patients that have been administered TILs. Such methods of treatment include obtaining from the patient a tumor fragment, contacting the tumor fragment with one or more cell culture mediums, thereby performing one or more expansions of population of TILs existing in the tumor, and producing one or more subsequent populations of TILs. The invention also provides methods of treating cancer in a patient exhibiting an increased or decreased level of expression of various biological markers.

The present application provides chimeric anti-CD27 antibody molecules and encoding nucleic acids and expression vectors thereof. The anti-CD27 antibody molecules of the present application can specifically bind to CD27 and have effects of stimulating lymphocyte proliferation, activating lymphocytes, etc.

The invention relates to the technical field of biological medicines, in particular to a maggot alcohol extract for improving chemotherapy immune injury, a preparation method of the maggot alcohol extract and application of the maggot alcohol extract in preparation of medicines, health-care products or functional foods for preventing or treating immune injury caused by chemotherapy medicines. It is found for the first time that the maggot alcohol extract has a remarkable protection effect on immune injury caused by chemotherapeutic drugs such as cyclophosphamide, the number of leukocytes and lymphocytes can be effectively increased, and immune organ atrophy is relieved. The maggot alcohol extract disclosed by the invention can be used for preparing medicines, health care products or functional foods for preventing or treating immune injury caused by chemotherapy, has the characteristics of multiple target spots, high efficiency and low toxicity, is simple and stable in preparation process, and has good development and application prospects.

The invention relates to the technical field of biological medicine, in particular to a truncated variant of a nuclear receptor LBD region and application of the truncated variant. According to the truncated variant of the nuclear receptor LBD structural domain provided by the invention, at least one amino acid is deleted at the C terminal. The ER, PR and GR truncated variants can induce transcriptional activation of a downstream signal channel under the condition that NTD is deleted, and a brand new treatment target is provided for patients with cancers such as prostatic cancer, breast cancer, endometrial cancer, acute lymphocytic leukemia, lymphoma, pancreatic cancer and lung cancer.

The present disclosure provides cancer cells that have been specifically sensitized to enhance their elimination by cytotoxic lymphocytes. The sensitized cancer cells, in some examples, overexpress one or more newly identified cytotoxic-lymphocyte sensitizing proteins, where the overexpression is achieved with, for example, a guide-based gene activation system, or transformation of the cancer cells with an open reading frame encoding the cytotoxic-lymphocyte sensitizing protein. The disclosure further provides cytotoxic lymphocytes engineered to overexpress antitumor enhancing ligands that act in a paracrine signaling mechanism to induce increased cytotoxic activity for the engineered lymphocytes. Also provided are methods for producing the sensitized cancer cells and engineered cytotoxic lymphocytes, and methods for treating or preventing a cancer.

The invention relates to clinical medicine, and more particularly to lymphology, surgery, plastic surgery and oncology, for treating lymphatic swelling in the case of primary or secondary lymphoedema in adults and children, inter alia accompanied by infectious complications, and even more particularly relates to methods for treating lymphoedema and to the use of accessible drugs in the treatment of lymphatic swelling at any stage and in any location. The claimed method for the lymphotropic treatment of lymphoedema involves consecutively preparing an injectable drug composition A containing an adrenergic alpha-1 receptor agonist and a glucocorticoid, administering same by lymphotropic interstitial injection by puncturing the interstitial tissue of the lymphatic region of interest and introducing the drug composition, preparing an injectable drug composition B containing a cholinesterase inhibitor, administering same by lymphotropic interstitial injection by puncturing the interstitial tissue of the lymphatic region of interest and introducing the drug composition, and also, if necessary, preparing an injectable drug composition C containing bovhyaluronidase azoximer, and administering same by interstitial injection by puncturing the interstitial tissue of the lymphatic region of interest. The technical result consists in improving the drainage of free fluid from the tissues and reducing limb swelling in the case of lymphoedema.

The present invention relates to a novel marrow infiltrating lymphocytes (MILs) population comprising a chimeric antigen receptor containing a B cell maturation antigen (BCMA) specific binding domain, and a method for preparing the same, and more particularly, to a novel marrow infiltrating lymphocytes (MILs) population comprising a chimeric antigen receptor containing a B cell maturation antigen (BCMA) specific binding domain. Specifically, the present invention provides a novel MILs group having characteristics of target cell specificity due to BCMA CAR and strong cytotoxicity to target cells, and a MILs culture method capable of providing the novel MILs group, the novel MILs group being useful as a novel immune anti-cancer therapy due to a high anti-cancer effect of the novel MILs group prepared by the method.

Provided herein are methods for manufacturing CAR-T cell products with high purity of TSCM subsets (>90%), independent of the variations from incoming leukapheresis. In some embodiments, to isolate the CCR7 and CD45RA double positive T cell subset, the processes described herein deplete CD45RO positive cells from leukapheresis and positively enrich for a CD4 and CD8 T cell population to isolation both TSCM and effector memory T cell (TEMRA) subsets, both of which positively express CD45RA and CCR7.

The application relates to the technical field of monoclonal antibodies, and specifically discloses an anti-p-Tau181 antibody and a preparation method and application thereof. The preparation method of the anti-p-Tau181 antibody comprises the following steps: taking a p-Tau181 polypeptide IPAKTPPAPK(pT)PPSSGEPPK as an immunogen, injecting the immunogen into experimental animals to perform an immune response, and obtaining spleen lymphocytes of the experimental animals; taking myeloma cells and the spleen lymphocytes to perform mixed culture to obtain fusion cells; culturing the fusion cells, obtaining supernatant, and performing ELISA detection; the polypeptide used for detection is the p-Tau181 polypeptide; taking the hybridoma cell strain with a positive detection result to perform counter screening with a p-Tau217 polypeptide, a p-Tau231 polypeptide and t-tau protein; screening a positive clone which has a reaction to the p-Tau181 polypeptide and has no reaction to the p-Tau217 polypeptide, the p-Tau231 polypeptide and the t-tau protein; performing multiple cloning screening; obtaining a hybridoma cell strain which can secrete antibodies every time; and taking the antibodies secreted by the hybridoma cell strain as the anti-p-Tau181 antibody. The anti-p-Tau181 antibody can be specifically combined with the p-Tau181, and thus can be used for detecting Alzheimer's disease.

Disclosed herein is a method for ex vivo expanding tumor-infiltrating lymphocytes for use in adoptive cell therapy (ACT). The method involves culturing tumor fragments from the subject in a culture medium containing IL-2 and a 41BB agonist in an amount effective to expand tumor-infiltrating lymphocytes with enriched tumor-reactivity and specificity. Also disclosed is a method for treating a tumor in a subject that involves treating the subject with nonmyeloablative lymphodepleting chemotherapy, and administering tumor-infiltrating lymphocytes expanded by the disclosed methods.

A three-dimensional (3D) lymphoid tissue model is provided, the model including a cellularized stromal compartment and a plurality of cellularized compartments including lymphocytes disposed within the stromal compartment; and a controlled fluid perfusion system configured to perfuse the model with a perfusion fluid. Methods of fabricating a 3D lymphoid tissue model and producing antibodies with the 3D lymphoid tissue model are also provided.

Blood-based biomarkers involving evaluation of membrane protein clustering (MPC) on peripherally circulating lymphocytes can identify individuals experiencing depression, schizophrenia, or bipolar disorder, while differentiating those that will respond to treatment from those that will not respond to treatment within the depressed populations. These markers can help diagnose and treat depression, schizophrenia, or bipolar disorder. Further, this diagnostic tool can identify individuals with treatment-resistant depression earlier. The disclosed automated method improves the throughput of blood-based biomarkers and can be standardized across multiple sites of blood collection / analysis. The automated approach performs similarly to human scorers for each method of blood smear collection in accurately obtaining cluster size means for each sample.

The invention provides a brain glioma immune microenvironment complexity assessment method and application, and the method comprises the following steps: obtaining m glioma samples, and carrying out transcriptome determination on each cell in each glioma sample to obtain transcriptional expression profile data of the cells; carrying out clustering analysis on transcriptional expression profile data of the single cells through K-means clustering, and preliminarily identifying lymphocytes and myeloid cells according to immune cell classical markers; carrying out clustering analysis on the identified transcription expression profile data of the lymphocytes and myeloid cells, and identifying n cell subgroups; calculating the enrichment score of the characteristic gene set of each cell subset in the glioma transcriptome sample, wherein the higher the score is, the higher the enrichment proportion of the cell subset in the sample is; and evaluating the complexity of immune cell enrichment in the glioma sample based on the enrichment score of the characteristic gene set. The immune cell infiltration complexity can be predicted, and the relationship between immune cell enrichment complexity and brain glioma prognosis can be identified.

The invention relates to a construction method and application of an immune system sheep-derived mouse model, and the construction method comprises the following steps: 1) taking an adaptively cultured severe immunodeficiency mouse, and injecting busulfan to inhibit the hematopoiesis of the mouse; 2) injecting sheep spleen lymphocytes into the body of the pre-treated immunodeficient mouse in an orbital vein manner; 3) after the sheep cells are transplanted in the step 2), detecting the cell proportions of sheep CD45 +, CD4 + and CD8 + in the peripheral blood of the mouse every week so as to detect the sheep CD45 +, CD4 + and CD8 + in the peripheral blood and / or tissues, and determining that the immune system sheep mouse is successfully constructed if the sheep CD45 +, CD4 + and CD8 + can be continuously detected for 13 weeks; (4) injecting and infecting Brucella into the abdominal cavity of the mouse in the step (3) to obtain the Brucella infected sheep-derived mouse model.According to the method, sheep spleen lymphocytes are transplanted into the mouse body to construct the immune system sheep-derived mouse, and a more effective and more convenient animal model is provided for studying diseases such as Brucella taking sheep as a host.